deltatrials
Unknown NA INTERVENTIONAL 2-arm NCT02312362

High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP (HFDS_abinterno)

HFDS ab Interno - to Compare Intraocular Pressure (IOP) Lowering Effect of Combined High Frequency Deep Sclerotomy ab Interno (HFDS ab Interno) With Phacoemulsification and Phacoemulsification Alone, in Primary Open Angle Glaucoma Patients

Sponsor: Oertli Instrumente AG

Updated 6 times since 2017 Last updated: Dec 5, 2014 Started: Nov 30, 2012 Primary completion: Jun 30, 2015 Completion: Dec 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Cataract and Glaucoma, this trial is ongoing. The trial is conducted by Oertli Instrumente AG and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Jan 2021 · 47 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown NA

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown NA

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown StatusUnknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status NA

  5. Feb 2017 — Jan 2021 [monthly]

    Unknown Status NA

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Unknown Status NA

    First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Oertli Instrumente AG
  • University of Geneva, Switzerland
Data source: Oertli Instrumente AG

For direct contact, visit the study record on ClinicalTrials.gov .